Hidroferol Hebdomadaire (Calcifediol Monohydrate)

Hidroferol Hebdomadaire is used in clinical practice to address conditions related to insufficient vitamin D status.

• Treatment of documented vitamin D deficiency in adults.
• Prevention of osteomalacia in individuals at risk.
• Adjunct therapy for osteoporosis management to support bone health.
• Support for patients with malabsorption syndromes that impair vitamin D synthesis.
• Seasonal prophylaxis of low vitamin D levels in populations with limited sun exposure.

• Calcifediol monohydrate is the 25‑hydroxy form of vitamin D3. After oral absorption, it bypasses hepatic 25‑hydroxylation and directly increases serum 25‑hydroxyvitamin D concentrations. The elevated metabolite binds to the vitamin D receptor (VDR) in target tissues, regulating gene transcription that enhances intestinal calcium and phosphate absorption, modulates bone remodeling, and influences immune function. The VDR‑mediated transcription also up‑regulates calbindin and other calcium‑transport proteins, facilitating efficient mineral uptake.

Adverse reactions to Hidroferol Hebdomadaire are generally mild, but rare serious events have been reported.

Common

• Transient hypercalcemia symptoms such as mild nausea or constipation.
• Headache or dizziness.
• Mild fatigue.
• Skin rash or mild pruritus.

Serious

• Persistent hypercalcemia leading to kidney stones or calcification of soft tissues.
• Severe allergic reactions including anaphylaxis.
• Acute pancreatitis associated with markedly elevated calcium levels.
• Hepatic dysfunction manifested by elevated liver enzymes.

Before initiating Hidroferol Hebdomadaire, certain safety considerations should be reviewed.

• Assess baseline serum 25‑hydroxyvitamin D, calcium, and phosphate levels.
• Use caution in patients with a history of hypercalcemia, renal stones, or granulomatous diseases.
• Adjust dose or avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²).
• Monitor calcium and renal function periodically during therapy.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Concomitant use with high‑dose vitamin D supplements may increase risk of toxicity.

Hidroferol Hebdomadaire may interact with other medicines that affect calcium balance or vitamin D metabolism.

Avoid

• High‑dose vitamin D or calcium supplements that could cause hypercalcemia.
• Thiazide diuretics, which reduce urinary calcium excretion.
• Medications that increase vitamin D activation such as anticonvulsants (e.g., phenobarbital, phenytoin).
• Sarcoidosis or other granulomatous disorders where endogenous vitamin D production is elevated.

Use with caution

• Bisphosphonates, as combined therapy may affect bone turnover monitoring.
• Corticosteroids, which can impair vitamin D metabolism and require dose adjustment.
• Loop diuretics, which increase calcium loss and may counteract the drug’s effect.
• Antiretroviral agents (e.g., efavirenz) that may lower vitamin D levels.